Kevin T. Sprott

Founder at Stablix, Inc.

Health Technology

Consumer Services

Commercial Services

Kevin T. Sprott active positions

Companies	Position	Start	End
Stablix, Inc. Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.	Director/Board Member	-	-
	Chief Operating Officer	25/05/2022	-
	Founder	-	-
	Corporate Officer/Principal	28/02/2021	25/05/2022

Companies	Position	Start	End
Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-	-
VERASTEM, INC.	Corporate Officer/Principal	-	-
IRONWOOD PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
SYROS PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

University of Kansas

Doctorate Degree

International

United States

Operational

Corporate Officer/Principal	5
Doctorate Degree	1
Director/Board Member	1

Sectoral

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	3
SYROS PHARMACEUTICALS, INC.	Health Technology
VERASTEM, INC.	Health Technology
IRONWOOD PHARMACEUTICALS, INC.	Health Technology

Private companies	2
Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.	Health Technology
Stablix, Inc. Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.	Commercial Services

Private companies

Health Technology

Commercial Services